Oligonucleotide Therapeutics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB504240613

Publication Date:

April 8, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global market for Oligonucleotide Therapeutics was estimated to be worth US$ 3678.1 million in 2023 and is forecast to a readjusted size of US$ 10970 million by 2030 with a CAGR of 16.7% during the forecast period 2024-2030
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Therapeutics by region & country, by Type, and by Application.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
麻豆原创 Segmentation
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type:
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oligonucleotide Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oligonucleotide Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Oligonucleotide Therapeutics Product Introduction
1.2 Global Oligonucleotide Therapeutics 麻豆原创 Size Forecast
1.3 Oligonucleotide Therapeutics 麻豆原创 Trends & Drivers
1.3.1 Oligonucleotide Therapeutics Industry Trends
1.3.2 Oligonucleotide Therapeutics 麻豆原创 Drivers & Opportunity
1.3.3 Oligonucleotide Therapeutics 麻豆原创 Challenges
1.3.4 Oligonucleotide Therapeutics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oligonucleotide Therapeutics Players Revenue Ranking (2023)
2.2 Global Oligonucleotide Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Oligonucleotide Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Oligonucleotide Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Oligonucleotide Therapeutics
2.6 Oligonucleotide Therapeutics 麻豆原创 Competitive Analysis
2.6.1 Oligonucleotide Therapeutics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Oligonucleotide Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antisense Oligonucleotide
3.1.2 Aptamer
3.1.3 Other
3.2 Global Oligonucleotide Therapeutics Sales Value by Type
3.2.1 Global Oligonucleotide Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Oligonucleotide Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Oligonucleotide Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Neuromuscular Diseases
4.1.2 ATTR
4.1.3 Hepatic VOD
4.1.4 Other
4.2 Global Oligonucleotide Therapeutics Sales Value by Application
4.2.1 Global Oligonucleotide Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Oligonucleotide Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Oligonucleotide Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Oligonucleotide Therapeutics Sales Value by Region
5.1.1 Global Oligonucleotide Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Oligonucleotide Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Oligonucleotide Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Oligonucleotide Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Oligonucleotide Therapeutics Sales Value, 2019-2030
5.2.2 North America Oligonucleotide Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Oligonucleotide Therapeutics Sales Value, 2019-2030
5.3.2 Europe Oligonucleotide Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Oligonucleotide Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Oligonucleotide Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Oligonucleotide Therapeutics Sales Value, 2019-2030
5.5.2 South America Oligonucleotide Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Oligonucleotide Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Oligonucleotide Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oligonucleotide Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Oligonucleotide Therapeutics Sales Value
6.3 United States
6.3.1 United States Oligonucleotide Therapeutics Sales Value, 2019-2030
6.3.2 United States Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oligonucleotide Therapeutics Sales Value, 2019-2030
6.4.2 Europe Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Oligonucleotide Therapeutics Sales Value, 2019-2030
6.5.2 China Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Oligonucleotide Therapeutics Sales Value, 2019-2030
6.6.2 Japan Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Oligonucleotide Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Oligonucleotide Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Oligonucleotide Therapeutics Sales Value, 2019-2030
6.9.2 India Oligonucleotide Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Oligonucleotide Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Biogen
7.1.1 Biogen Profile
7.1.2 Biogen Main Business
7.1.3 Biogen Oligonucleotide Therapeutics Products, Services and Solutions
7.1.4 Biogen Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Biogen Recent Developments
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Profile
7.2.2 Sarepta Therapeutics Main Business
7.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Products, Services and Solutions
7.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Sarepta Therapeutics Recent Developments
7.3 Jazz Pharmaceuticals
7.3.1 Jazz Pharmaceuticals Profile
7.3.2 Jazz Pharmaceuticals Main Business
7.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Products, Services and Solutions
7.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Bausch & Lomb Recent Developments
7.4 Bausch & Lomb
7.4.1 Bausch & Lomb Profile
7.4.2 Bausch & Lomb Main Business
7.4.3 Bausch & Lomb Oligonucleotide Therapeutics Products, Services and Solutions
7.4.4 Bausch & Lomb Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Bausch & Lomb Recent Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Profile
7.5.2 Alnylam Pharmaceuticals Main Business
7.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Products, Services and Solutions
7.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Alnylam Pharmaceuticals Recent Developments
7.6 Dynavax Technologies
7.6.1 Dynavax Technologies Profile
7.6.2 Dynavax Technologies Main Business
7.6.3 Dynavax Technologies Oligonucleotide Therapeutics Products, Services and Solutions
7.6.4 Dynavax Technologies Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Dynavax Technologies Recent Developments
7.7 Kastle therapeutics
7.7.1 Kastle therapeutics Profile
7.7.2 Kastle therapeutics Main Business
7.7.3 Kastle therapeutics Oligonucleotide Therapeutics Products, Services and Solutions
7.7.4 Kastle therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Kastle therapeutics Recent Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Profile
7.8.2 Akcea Therapeutics Main Business
7.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Products, Services and Solutions
7.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Akcea Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Oligonucleotide Therapeutics Industrial Chain
8.2 Oligonucleotide Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oligonucleotide Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Oligonucleotide Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.